Relevant diseases or clinical situations which may increase the patient's risk Active immune-mediated diseases including: connective tissue diseases, uveitis, sarcoidosis, inflammatory bowel disease, multiple sclerosis, (non-infectious) pneumonitis. History of other significant cardiovascular diseases or vascular diseases within the last months prior to randomization that, in the investigator's opinion, may pose a risk to the patient on VEGF inhibitor therapy. Hepatobiliary diseases including biliary tract diseases, autoimmune hepatitis, inflammation, fibrosis, cirrhosis of liver caused by viral, alcohol, or genetic reasons; Gilberts disease is allowed if total bilirubin (TBil) is =< . x ULN Severe underlying cardiac or renal diseases Concomitant diseases/conditions: MEDICAL HISTORY AND CONCURRENT DISEASES Central nervous system (CNS) diseases and major psychiatric diseases or inability to comply to the protocol procedures Patients with criteria of probable or definitive adenoviral diseases. History of or current active autoimmune diseases Participants with chronic autoimmune diseases Severe hypersensitivity reactions to monoclonal antibodies, known hypersensitivity to the investigational medicinal products or to one or more of the excipients, autoimmune diseases (inflammatory bowel diseases, interstitial lung disease, or pulmonary fibrosis), and live vaccines within days prior to study entry. Any of the following concomitant diseases/conditions: Uncontrolled diseases other than cancer will be excluded. Subjects with chronic diseases that are well controlled (e.g., diabetes mellitus, hypertension) are eligible. Patients with systemic diseases which may be associated with unacceptable anesthetic/operative risk Active or chronic autoimmune diseases Active autoimmune diseases requiring systemic treatments Patients with Gilbert's syndrome or other heritable diseases of bile processing. Patients with uncontrolled diseases other than cancer will be excluded Known history of HIV or autoimmune diseases requiring immunosuppressant drugs History of autoimmune diseases (such as systemic lupus erythematosus [SLE], Wegener's, Wegener's granulomatosis, polyarteritis nodosa); Note: Prior autoimmune diseases are allowed as long as clinically stable Other immunoregulatory or immunodeficiency diseases, such as multiple sclerosis Medical history and concurrent diseases: Hepatobiliary diseases including biliary tract diseases, autoimmune hepatitis, inflammation, fibrosis, cirrhosis of liver caused by viral, alcohol, or genetic reasons; Gilberts disease is allowed if TBil is =< . x ULN Diseases or conditions that obscure toxicity or dangerously alter drug metabolism Patients with active autoimmune skin diseases such as psoriasis or other active autoimmune diseases such as rheumatoid arthritis Patients with autoimmune diseases that require immunosuppressive medications are excluded Patients with other significant diseases or disorders that, in the investigators opinion, would exclude them from the study Autoimmune disorders and other diseases that compromise or impair the immune system. Active or chronic autoimmune diseases Concomitant diseases/conditions: Subjects with active autoimmune diseases or history of autoimmune diseases should be excluded. Medical History and Concurrent Diseases Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness Hepatobiliary diseases including biliary tract diseases, autoimmune hepatitis, inflammation, fibrosis, cirrhosis of liver caused by viral, alcohol, or genetic reasons; Gilberts disease is allowed if TBil is =< . x ULN Other serious diseases (hematological, hepatic, renal, respiratory, central nervous system, autoimmune or psychiatric) Any evidence of severe or uncontrolled diseases Any of the following cardiac diseases currently or within the last months: Active immune-mediated diseases including: connective tissue diseases, uveitis, sarcoidosis, inflammatory bowel disease, multiple sclerosis. Autoimmune diseases or chronic decompensated diseases Patients with a history of autoimmune diseases except for Hashimoto's thyroiditis Patients with uncontrolled autoimmune diseases. Diagnosed with one of the following diseases: Psychiatric conditions/diseases that impair the ability to give informed consent or to adequately co-operate Concomitant treatment with chemotherapeutic agents for diseases other than malignancy Diseases or conditions that obscure toxicity or dangerously alter drug metabolism History of autoimmune diseases Has a medical history of clinically significant lung diseases Hepatobiliary diseases including biliary tract diseases, autoimmune hepatitis, inflammation, fibrosis, or cirrhosis of liver caused by viral, alcohol, or genetic reasons. Gilbert's disease is allowed if total bilirubin is ?. ULN. Subjects with known photosensitivity diseases Any evidence of severe or uncontrolled diseases History of autoimmune diseases Concomitant diseases/conditions Medical History and Concurrent Diseases No pituitary diseases or growth Major medical conditions involving the immune system such as autoimmune and/or inflammatory diseases Medical condition such as uncontrolled infection (including human immunodeficiency virus [HIV]), uncontrolled diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other collagen vascular diseases) Individuals with a history of photosensitive diseases including, but not limited to, lupus erythematosus, pseudoporphyria, or other diseases that in the opinion of the study physician would pose a risk to the subject or interfere with the study History of\r\n* Any invasive malignancy within the past years, with the exception of non-melanoma skin cancer\r\n* Chronic renal diseases or liver cirrhosis\r\n* Diseases such as anemia, peptic ulcer, gastrointestinal bleeding, active colitis and inflammatory bowel disease\r\n* Hemorrhagic stroke or uncontrolled hypertension Acquired immunosuppressive diseases such as active human immunodeficiency virus (HIV) infection or congenital diseases of immunity Subject has one of the following underlying diseases: Have known history of kidney diseases Diseases of the soft or hard oral tissues Personal history of hepatitis or other liver diseases Participants with genetic diseases of the liver that may complicate review of safety data Immune system disorders, respiratory diseases, kidney or liver diseases or any other medical disorders that may affect biomarker data Concomitant diseases/conditions: Medical History and Concurrent Diseases Diagnosis of of the following diseases: